Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation

Blood

Volumn 106, Issue 13, 2005, Pages 4407-4411

  Mohty, Mohamad ^a   Blaise, Didier ^a   Faucher, Catherine ^a   Vey, Norbert ^a   Bouabdallah, Reda ^a   Stoppa, Anne Marie ^a   Viret, Frederic ^a   Gravis, Gwenaelle ^a   Olive, Daniel ^a   Gaugler, Béatrice ^b  

^a Institut Paoli Calmettes ^*

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD27 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 12P70; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; BONE MARROW CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; LYMPHATIC SYSTEM TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOCYTE; ONSET AGE; PREDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; SOLID TUMOR; STATISTICAL ANALYSIS; T LYMPHOCYTE;

EID: 28844506300     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2919     Document Type: Article

References (27)

1. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-1016.
2. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood. 1995;86:890-899.
3. Krenger W, Ferrara JL. Dysregulation of cytokines during graft-versus-host disease. J Hematother. 1996;5:3-14.
4. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553-558.
5. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
6. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
7. Niederwieser D, Maris M, Shizuru JA, et al. Lowdose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-1629.
8. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756-762.
9. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102:470-476.
10. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia. 2003;17:2168-2177.
11. Mohty M, Blaise D, Faucher C, et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia. 2005;19:1-6.
12. Cox DR. Regression models and life-tables (with discussions), Series B. J R Stat Soc. 1972;34:187-220.
13. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183-1186.
14. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-146.
15. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant. 1999;5:347-356.
16. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996;15:50-73.
17. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft-versushost disease in mice. J Immunol. 1996;157:689-699.
18. Krenger W, Cooke KR, Crawford JM, et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graftversus-host disease. Transplantation. 1996;62:1278-1285.
19. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versushost disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol. 1994;153:4040-4047.
20. Guy-Grand D, Vassalli P. Gut injury in mouse graft-versus-host reaction: study of its occurrence and mechanisms. J Clin Invest. 1986;77:1584-1595.
21. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vshost disease. J Exp Med. 1987;166:1280-1289.
22. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25:1216-1217.
23. Reddy P, Ferrara JL. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med. 2003;141:365-371.
24. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood. 2004;104:889-894.
25. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
26. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:340-349.
27. Mohty M, Bagattini S, Chabannon C, et al. CD8+ T cell dose affects development of acute graft-vshost disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2004;32:1097-1102.